Resectable Esophagogastric Adenocarcinoma
1 clinical trials · Condition
◉ Watch Resectable Esophagogastric Adenocarcinoma
| Record | Firm | Date |
|---|---|---|
| A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma (NCT07059299) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2025-12-12 |
Track Resectable Esophagogastric Adenocarcinoma automatically
Every clearance here is in the API, with alerts when new ones post.